Cite
HARVARD Citation
Singh, R. et al. (2021). Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study. Clinical and translational science. 14 (2), pp. 671-682. [Online].